There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dova Pharmaceuticals Inc (DOVA), Ziopharm Oncology (ZIOP) and G1 Therapeutics Inc (GTHX) with bullish sentiments.
Dova Pharmaceuticals Inc (DOVA)
Dova Pharmaceuticals Inc received a Buy rating and a $18 price target from H.C. Wainwright analyst Joseph Pantginis today. The company’s shares closed yesterday at $6.07, close to its 52-week low of $5.93.
Pantginis commented:
“Valuation and risks to price target achievement. We are instituting a Buy rating and $18 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. We currently add an extra layer of conservatism by employing a discount rate of 30% vs. our standard 15%, which we believe appropriately takes into consideration the overall risk profile fo the company currently.”
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -24.8% and a 20.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dova Pharmaceuticals Inc with a $38 average price target.
See today’s analyst top recommended stocks >>
Ziopharm Oncology (ZIOP)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ziopharm Oncology, with a price target of $5.50. The company’s shares closed yesterday at $2.30, close to its 52-week low of $1.90.
Ramakanth noted:
“We are maintaining our Buy rating of ZIOP and our 12-month price target of $5.50 per diluted share. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues until 2027 assuming a 12% discount rate and a 4% terminal growth rate. We derive an rNPV of $897M for pipeline products and add $40M in cash and cash equivalents to arrive at a 12-month price target of $5.63 per diluted share, which we round to $5.50.”
According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -5.0% and a 31.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.
Currently, the analyst consensus on Ziopharm Oncology is a Moderate Buy with an average price target of $5.25.
G1 Therapeutics Inc (GTHX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics Inc, with a price target of $75. The company’s shares closed yesterday at $28.75.
White wrote:
“We base our $75 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC.”
According to TipRanks.com, White is a 5-star analyst with an average return of 11.8% and a 42.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $74.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
